Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.005 | 0.013 | 0.013 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0101 | 0.2879 | 1 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0233 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.005 | 0.013 | 0.5 |
Toxoplasma gondii | melibiase subfamily protein | 0.0101 | 0.2879 | 1 |
Onchocerca volvulus | 0.0048 | 0 | 0.5 | |
Brugia malayi | Melibiase family protein | 0.0067 | 0.1066 | 0.1066 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0101 | 0.2879 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.005 | 0.013 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.005 | 0.013 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0233 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.005 | 0.013 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.005 | 0.013 | 0.5 |
Trichomonas vaginalis | alpha-galactosidase/alpha-N-acetylgalactosaminidase, putative | 0.0067 | 0.1066 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0067 | 0.1066 | 0.0948 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0101 | 0.2879 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.005 | 0.013 | 0.5 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0233 | 1 | 1 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0067 | 0.1066 | 0.3703 |
Leishmania major | hypothetical protein, conserved | 0.005 | 0.013 | 0.5 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0067 | 0.1066 | 0.3703 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0101 | 0.2879 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.